The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
Open accessAbstract
In a subset of patients with primary pulmonary hypertension (PPH), high doses of oral calcium-channel blockers (CCB) produce a sustained clinical and haemodynamic improvement. However, significant side-effects have been reported during acute testing with CCB. Therefore, to identify accurately patients who may benefit from long-term CCB therapy, there is a need for a safe, potent and short-acting vasodilator. The aim of this study was to compare the acute response to inhaled nitric oxide (NO) and oral high doses of CCB in 33 consecutive patients with PPH. A significant acute vasodilator response was defined by a fall in both mean pulmonary artery pressure and total pulmonary resistance by >20%. Ten patients responded acutely to NO, nine of whom responded acutely to CCB, without any complications. The 23 other patients failed to respond to NO and CCB. In these nonresponders, nine serious adverse events were observed with CCB (38%). There was no clinical or baseline haemodynamic feature predicting acute vasodilator response. Long-term oral treatment with CCB was restricted to the nine acute responders and a sustained clinical and haemodynamic improvement was observed in only six patients. In primary pulmonary hypertension, the acute response rate to high doses of calcium-channel blockers is low (27%). Serious adverse reactions to high doses of calcium-channel blockers during acute testing are frequently observed in nonresponders. It is concluded that nitric oxide may be used as a screening agent for safely identifying patients with primary pulmonary hypertension who respond acutely to calcium-channel blockers and may benefit from long-term treatment with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
Primary Pulmonary Hypertension
Rubin, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360207 · Cited by 1,726
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
PEPKEZABA, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92033-x · Cited by 1,055
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.
Rubin, L. J., Groves, B. M., Reeves, J. T., Frosolono, M., Handel, F., & Cato, A. E. (1982) · Circulation · doi:10.1161/01.cir.66.2.334 · Cited by 316
Sitbon, O., Brenot, F., Denjean, A., Bergeron, A., Parent, F., Azarian, R., Herve, P., Raffestin, B., & Simonneau, G. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842196 · Cited by 315
Self-citationWeir, E. K., Rubin, L. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Elliott, C. G., Fishman, A. P., Goldring, R. M., Groves, B. M., et al. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.6.1623 · Cited by 186
The case for treatment of selected patients with primary pulmonary hypertension.
Reeves, J. Τ., Groves, B. Μ., & Turkevich, D. (1986) · PubMed · doi:10.1164/arrd.1986.134.2.342 · Cited by 125
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension
Sitbon, O., Brénot, F., Denjean, A., Bergeron, A., Parent, F., Azarian, R., Hervé, P., Raffestin, B., & Simonneau, G. (1996) · Réanimation Urgences · doi:10.1016/s1164-6756(96)80065-x · Cited by 109
Self-citationRich, S., & Kaufmann, E. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90556-o · Cited by 91
Cited by
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
Sitbon, O., Humbert, M., Jaïs, X., Ioos, V., Hamid, A. M., Provencher, S., Garcia, G., Parent, F., Hervé, P., & Simonneau, G. (2005) · Circulation · doi:10.1161/circulationaha.104.488486 · Cited by 1,255
Self-citationMedical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Self-citationPulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Metadata
- Authors
- Sitbon, O., Humbert, M., Jagot, J., Taravella, O., Fartoukh, M., Parent, F., Herve, P., & Simonneau, G.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 1998-08-01
- Volume
- 12
- Issue
- 2
- Pages
- 265-270
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2118073788
- Cited by
- 301
- References
- 11
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. https://app.cochat.ai/papers/10.1183/09031936.98.12020265
- The paper
- Sitbon, O., Humbert, M., Jagot, J., Taravella, O., Fartoukh, M., Parent, F., Herve, P., & Simonneau, G. (1998). Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. European Respiratory Journal. https://doi.org/10.1183/09031936.98.12020265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
